During the dose-escalation phase (usually lasting 16 to 20 weeks), weekly losses tend to be smaller because you're on lower doses
DEXA scans were performed and assessed by blinded personnel, and statistical analyses were planned prior to unblinding at the end of the treatment period
Lupita R
Amycretin, Novo Nordisks oral dual GLP-1/amylin agonist, showed 13% weight loss in early trials, signaling a move toward multi-pathway oral therapies
Importantly, their influence extends to skeletal muscle, where GLP-1 RAs promote glucose uptake via the AMP-activated protein kinase pathway, increase vascular blood flow, and mitigate glucotoxicity, thereby supporting muscle protein synthesis and inhibiting catabolic pathways [14, 15]
Mini reviews in medicinal chemistry